This website is intended for healthcare professionals only

touchNEUROLOGY

Search

Trending Topic

Developed by Touch

European Stroke Organisation Conference 2026: Expanding the boundaries of acute stroke care

Federica Rizzo, Ettore Nicolini, Antonio Ciacciarelli

The 12th European Stroke Organisation Conference (Maastricht, May 6–8, 2026) was dominated by studies testing the limits of acute stroke therapy, from thrombectomy and neuroprotection to secondary prevention. Supplementary Table 1 provides a comprehensive overview of the major studies presented during the conference. The large-core indication for thrombectomy is recent, and the ATLAS (Endovascular thrombectomy […]

touchREVIEWS in Neurology. 2026;22(1):Online ahead of journal publication

Alzheimer's Disease and Dementia

Alzheimer’s Disease

Published Online: Nov 7th 2012

The challenges of Alzheimer’s Disease for both the patient and caregiver.

Trending Topic

Developed by Touch

GRADUATE: Targeting the NLRP3 inflammasome in Alzheimer’s disease

Gennaro Pagano

Could NLRP3 be the missing link between amyloid pathology and tau-mediated neurodegeneration? Dr Gennaro Pagano explains how insights from the GRADUATE trial is informing the next generation of Alzheimer’s disease therapies and advancing our understanding of neuroinflammation. touchNEUROLOGY coverage of AAIC 2026 Late-breaking reverse translational analyses from the Phase III GRADUATE programme presented at the […]

Related Videos in Alzheimer's Disease and Dementia

CT1812 demonstrates promising biomarker data in Phase 2 SHINE study, AD/PD 2025

In this interview, we speak with Dr Anthony Caggiano, Chief Medical Officer and Head of R&D at Cognition Therapeutics, and Lisa Ricciardi, the company’s Chief Executive Officer. They discuss the design and findings of the phase II SHINE trial evaluating zervimesine (CT-1812) in mild to moderate Alzheimer’s disease, including important biomarker and clinical insights presented at recent international conferences. They also reflect on promising data from a study in dementia with Lewy bodies (DLB) and how these results are shaping the company’s next steps.

EAN 2024: Late-breakers in movement disorders, aging and dementia

Miguel Miranda

Key topics and highlights from the Late-Breaking News session at the European Academy of Neurology (EAN) meeting are discussed in this interview, where Dr. Miguel Miranda provides valuable insights. He addresses unmet medical needs in dementia, aging, and movement disorders, drawing on his experience from Unidade Funcional de Neurologia, Hospital de Cascais Dr. José de Almeida, Cascais, Portugal, as he joins touchNEUROLOGY.

Developed by Touch

Kristian Steen Frederiksen, EAN 2023: The new EAN guidelines

Dr Kristian Steen Frederiksen (Danish Dementia Research Center, Denmark, Copenhagen) summarizes some of the key updates to the EAN guidelines, and the take-home messages presented at the annual European Academy of Neurology (EAN), July 1–4, 2023. Disclosures: Kristian Steen Frederiksen has no ...

Developed by Touch

Kristian Steen Frederiksen, EAN 2023: Highlights in Alzheimer's disease and dementia

Dr Kristian Steen Frederiksen (Danish Dementia Research Center, Denmark, Copenhagen) discusses his highlights from the annual European Academy of Neurology (EAN), July 1–4, 2023 in the field of Alzheimer's disease and dementia. Disclosures:Kristian Steen Frederiksen has no financial or non-financial conflicts ...

Developed by Touch

Kristen George, AAIC 2022: Experiences of discrimination on cognitive function and ageing among the oldest old: The LifeAfter90 (LA90) Study

The LifeAfter90 (LA90) Study aims to understand what cognitive ageing and dementia look like among individuals aged 90 and above. In this interview, Dr Kristen George (University of California Davis School of Medicine, University of California, Davis, CA, USA) discussed what ...

Developed by Touch

Claire Sexton: Highlights of AAIC 2022

The Alzheimer’s Association International Conference (AAIC) is the largest and most influential meeting dedicated to advancing Alzheimer’s and dementia research. Each year, it gathers researchers to share discoveries that'll lead to methods of prevention and treatment and improvements ...

Developed by Touch

Dr Jennifer Bute: Living with dementia - the importance of laughter and hope

Dr Jennifer Bute is a retired GP living with dementia. She shares her experiences of diagnosis and describes the strategies that are helpful for her. Jennifer also highlights the importance of laughter, engagement and hope. Touch Medical Media is sharing ...

Developed by Touch

Elisabeth Hendrickx Van de Craen, EAN 2022: Rare ABCA7 mutations and Alzheimer’s disease

ABCA7 is a major risk gene for Alzheimer’s disease (AD), and rare premature termination codon and missense mutations are enriched in AD patients. Elisabeth Hendrickx Van de Craen (VIB-UAntwerpen, University of Antwerp, Antwerp, Belgium) spoke with touchNEUROLOGY about the ...

Developed by Touch

Oliver Cousins, EAN 2022: Effect of TREM2 on neurodegenerative diagnosis

The effect of TREM2 on neurodegenerative diagnosis, cognitive profile and brain structure are discussed in this touchNEUROLOGY interview with Dr Oliver Cousins (King's College London, London, UK). Microglial genes are risk factors for neurodegenerative disease. This study investigated the association ...

Sharon Cohen, AD/PD 2022: Achieving timely, accurate, neuropathological diagnosis and precision management in early Alzheimer's disease

Dr Sharon Cohen joins touchNEUROLOGY to discuss the challenges in diagnosing Alzheimer’s disease (AD) at an early stage, the most exciting recent developments in diagnostic criteria, genetic testing, and neuroimaging techniques. Dr Cohen also talks through the recent developments ...

Developed by Touch

Sharon Cohen, AAN 2022: Long-term safety and efficacy of aducanumab in Alzheimer's disease - Baseline EMBARK data from EMERGE, ENGAGE, and PRIME

Aducanumab is a human monoclonal antibody targeting soluble and insoluble amyloid beta (Aβ) aggregates. Aducanumab was approved in June 2021 for the treatment of mild cognitive impairment due to Alzheimer’s disease or mild dementia due to Alzheimer’s disease by ...

Developed by Touch

Tim Bartels: Highlights at AD/PD 2022

Dr Tim Bartels (UK Dementia Research Institute, University College London, London, UK) joins touchNEUROLOGY to discuss the highlights from this year's AD/PD 2022 conference. He discusses some of his personal highlights in the field of new therapeutics for neurodegeneration, and ...

Latest articles videos and clinical updates - straight to your inbox

Sign Up

Login

Sign Up FREE

Log into your Touch Account

Keep track of your clinical interests and newsletter subscriptions.

Error:

Forgot Password?

Or log in with

By proceeding, you agree to our terms & conditions.

For information about how we
use your data, see our privacy policy.

Register now for FREE Access

Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.

Sign up with an Email

Sign up with Google

Sign up with Facebook

Sign up with LinkedIn

Sign up with Microsoft

Already have an Account?

Login

Sign up with an Email

Or use a Social Account.

Error:

By clicking sign up you agree to the website
terms & conditions and privacy policy.

Register now for FREE access

Already registered? Login below.

Register

Login